Preventive effects of a natural anti-inflammatory agent Salvianolic acid A on acute kidney injury in mice

Food Chem Toxicol. 2020 Jan:135:110901. doi: 10.1016/j.fct.2019.110901. Epub 2019 Oct 23.

Abstract

Acute kidney injury (AKI) is an abrupt loss of kidney function with high mortality. Inflammatory is considered driving the progression of AKI. Salvianolic acid A (SA), one of the major ingredients of Salvia miltiorrhiza Bunge, displays plenty of biological effects. Herein, the effect of SA on lipopolysaccharide (LPS)-induced AKI in mice and further related mechanism in inflammatory cells were explored. In vivo experiments demonstrated that SA significantly ameliorated LPS-challenged AKI by preventing glomerulus atrophy and decreasing plasma creatinine and blood urea nitrogen (BUN) levels. Meanwhile, SA significantly decreased the release of serum inflammatory cytokines and blocked macrophage infiltration in damaged renal tissue. In in vitro studies, SA significantly decreased TNF-α and IL-6 release levels and altered the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) in LPS-stimulated macrophages, which were consistent with the results from in vivo experiments. Furthermore, SA that bound to Toll-Like Receptor 4 (TLR4) was able to reduce endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) generation in response to LPS stimulation. All silence of TLR4 gene, ROS scavenger and Ca2+ chelator decreased inflammatory cytokines releases. Taken together, SA could be used as a potential therapeutic agent for preventing AKI by suppressing inflammatory responses.

Keywords: Acute kidney injury; Inflammatory; Lipopolysaccharide; Oxidative stress; Salvianolic acid A.

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / prevention & control*
  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Caffeic Acids / therapeutic use*
  • Endoplasmic Reticulum Stress / drug effects
  • Lactates / therapeutic use*
  • Lipopolysaccharides
  • MAP Kinase Signaling System / drug effects
  • Macrophages / metabolism
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Myeloid Differentiation Factor 88 / metabolism
  • Protective Agents / therapeutic use*
  • RAW 264.7 Cells
  • Reactive Oxygen Species / metabolism
  • Toll-Like Receptor 4 / metabolism

Substances

  • Anti-Inflammatory Agents
  • Caffeic Acids
  • Lactates
  • Lipopolysaccharides
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • Protective Agents
  • Reactive Oxygen Species
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • salvianolic acid A